ATHE vs. MTEM, NCNA, CMMB, ADXN, GRTX, UPC, AEZS, GHSI, MBRX, and MIRA
Should you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include Molecular Templates (MTEM), NuCana (NCNA), Chemomab Therapeutics (CMMB), Addex Therapeutics (ADXN), Galera Therapeutics (GRTX), Universe Pharmaceuticals (UPC), Aeterna Zentaris (AEZS), Guardion Health Sciences (GHSI), Moleculin Biotech (MBRX), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical preparations" industry.
Alterity Therapeutics (NASDAQ:ATHE) and Molecular Templates (NASDAQ:MTEM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, community ranking, analyst recommendations, valuation and risk.
Molecular Templates received 339 more outperform votes than Alterity Therapeutics when rated by MarketBeat users. Likewise, 67.32% of users gave Molecular Templates an outperform vote while only 60.00% of users gave Alterity Therapeutics an outperform vote.
In the previous week, Molecular Templates had 4 more articles in the media than Alterity Therapeutics. MarketBeat recorded 5 mentions for Molecular Templates and 1 mentions for Alterity Therapeutics. Alterity Therapeutics' average media sentiment score of 0.00 beat Molecular Templates' score of -0.09 indicating that Alterity Therapeutics is being referred to more favorably in the media.
Molecular Templates has higher revenue and earnings than Alterity Therapeutics.
Alterity Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Comparatively, Molecular Templates has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500.
Alterity Therapeutics currently has a consensus price target of $7.00, indicating a potential upside of 257.14%. Given Alterity Therapeutics' higher probable upside, equities analysts clearly believe Alterity Therapeutics is more favorable than Molecular Templates.
Alterity Therapeutics has a net margin of 0.00% compared to Molecular Templates' net margin of -57.92%. Alterity Therapeutics' return on equity of 0.00% beat Molecular Templates' return on equity.
2.1% of Alterity Therapeutics shares are owned by institutional investors. Comparatively, 95.5% of Molecular Templates shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by insiders. Comparatively, 13.4% of Molecular Templates shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Alterity Therapeutics beats Molecular Templates on 8 of the 15 factors compared between the two stocks.
Get Alterity Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alterity Therapeutics Competitors List
Related Companies and Tools
